USPTO rejects Celgene bid for Bass sanctions
28-09-2015
Celgene calls for Kyle Bass sanctions
31-07-2015
13-08-2015
NicoElNino / Shutterstock.com
Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review (IPR) filing.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass; Celgene; Coalition for Affordable Drugs; pharmaceuticals; inter partes review; PTAB